Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance

Y Wang, Q Liu, H Chen, J You, B Peng, F Cao… - Anti-Cancer …, 2018 - journals.lww.com
The development of resistance to therapy continues to be a serious clinical problem in lung
cancer management. Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) …
被引用次数：15 相关文章

Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance

Y Wang, Q Liu, H Chen, J You, B Peng… - Anti-cancer …, 2018 - pubmed.ncbi.nlm.nih.gov
The development of resistance to therapy continues to be a serious clinical problem in lung
cancer management. Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) …

Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance

Y Wang, Q Liu, H Chen, J You, B Peng, F Cao… - Anti-Cancer …, 2018 - ingentaconnect.com
The development of resistance to therapy continues to be a serious clinical problem in lung
cancer management. Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) …

Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance

Y Wang, Q Liu, H Chen, J You, B Peng, F Cao… - Anti-Cancer …, 2018 - inserm.hal.science
The development of resistance to therapy continues to be a serious clinical problem in lung
cancer management. Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) …

Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance.

Y Wang, Q Liu, H Chen, J You, B Peng, F Cao… - Anti-cancer …, 2018 - europepmc.org
The development of resistance to therapy continues to be a serious clinical problem in lung
cancer management. Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) …